In vivo biotransformations of antibody–drug conjugates

Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates

(2015) Magdalena Dorywalska et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

(2015) Paresh Agarwal et al.   BIOCONJUGATE CHEMISTRY

An Immunosuppressive Antibody–Drug Conjugate

(2015) Rongsheng E. Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Measurement of in Vivo Drug Load Distribution of Cysteine-Linked Antibody–Drug Conjugates Using Microscale Liquid Chromatography Mass Spectrometry

(2014) Shawna Mae Hengel et al.   ANALYTICAL CHEMISTRY

Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers

(2014) James T. Patterson et al.   BIOCONJUGATE CHEMISTRY

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy

(2014) L. Nathan Tumey et al.   BIOCONJUGATE CHEMISTRY

Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling

(2014) R. Cohen et al.   CANCER RESEARCH

Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering

(2014) Thomas H. Pillow et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

(2014) Andreas Maderna et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

(2014) Dowdy Jackson et al.   PLoS One

A general approach to site-specific antibody drug conjugates

(2014) Feng Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid, Stable, Chemoselective Labeling of Thiols with Julia-Kocieński-like Reagents: A Serum-Stable Alternative to Maleimide-Based Protein Conjugation

(2013) Narihiro Toda et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

(2013) Scott C. Jeffrey et al.   BIOCONJUGATE CHEMISTRY

A New Reagent for Stable Thiol-Specific Conjugation

(2013) George Badescu et al.   BIOCONJUGATE CHEMISTRY

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Insights into antibody–drug conjugates: bioanalysis and biomeasures in discovery

(2013) Tracey Clark et al.   Bioanalysis

Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper

(2013) Boris Gorovits et al.   Bioanalysis

Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics

(2013) Surinder Kaur et al.   Bioanalysis

Novel detection of DNA-alkylated adducts of antibody–drug conjugates with potentially unique preclinical and biomarker applications

(2013) Lourdes Thevanayagam et al.   Bioanalysis

PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability

(2013) Azher Hussain et al.   Bioanalysis

ADME of Antibody–Maytansinoid Conjugates

(2012) Hans K. Erickson et al.   AAPS Journal

Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics

(2012) Daniela Bumbaca et al.   AAPS Journal

Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism

(2012) Ben-Quan Shen et al.   CURRENT DRUG METABOLISM

Disulfide Linkage: A Potent Strategy in Tumor-Targeting Drug Discovery

(2012) J. Wang et al.   CURRENT MEDICINAL CHEMISTRY

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

(2012) H. K. Erickson et al.   MOLECULAR CANCER THERAPEUTICS

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Pharmacokinetic Considerations for Antibody Drug Conjugates

(2012) Kedan Lin et al.   PHARMACEUTICAL RESEARCH

Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism

(2011) Xiuxia Sun et al.   BIOCONJUGATE CHEMISTRY

Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage

(2011) Brenda A. Kellogg et al.   BIOCONJUGATE CHEMISTRY

Abstract 2587:In vitroplasma stability of human anti-CD70 antibody drug conjugate, MDX-1203

(2011) Janette Sung et al.   CANCER RESEARCH

Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I

(2011) George A. Ellestad   CHIRALITY

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

The development of pyrrolobenzodiazepines as antitumour agents

(2011) John A Hartley   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates

(2011) Robert Y. Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer

(2011) Robert Yongxin Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

(2010) Joel M. Reid et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

(2010) M. Lopus et al.   MOLECULAR CANCER THERAPEUTICS

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

Fundamental Relationships between Structure, Reactivity, and Biological Activity for the Duocarmycins and CC-1065

(2009) Karen S. MacMillan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

An Additional Spirocyclization for Duocarmycin SA

(2008) Karen S. MacMillan et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY